Ivax paclitaxel
Executive Summary
First generic version of Bristol's Taxol will begin shipping within three weeks, Ivax said Sept. 20. Ivax will have 180 days of exclusivity following the launch of 30 mg/5 mL, 150 mg/25 mL and 300 mg/50 mL multiple-dose vials. Ivax made the announcement following the tentative approval of Mylan's 30 mg/5 mL paclitaxel ANDA. Ivax' ANDA was approved Sept. 15 (1"The Pink Sheet" Sept. 18, p. 3)
You may also be interested in...
Ivax Generic Paclitaxel Clears FDA; Bristol Patent Case Pending In N.Y.
FDA has approved Ivax' generic version of the anticancer agent paclitaxel despite Bristol-Myers Squibb's announced relisting of a recently issued patent in the "Orange Book."
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials